AP5Z1 affects hepatocellular carcinoma growth and autophagy by regulating PTEN ubiquitination and modulating the PI3K/Akt/mTOR pathway

Zhipeng Quan, Bo Peng, Kai Hu, Lixing Liang, Mingjiang Liu, Lijuan Liao, Shilian Chen, Jing Qin, Songqing He, Zeyuan LiJournal of Translational Medicine 2025 · DOI

TL;DR

Researchers have identified AP5Z1 as a potent oncogenic driver in hepatocellular carcinoma (HCC) that accelerates tumor growth by dismantling the tumor suppressor PTEN. By recruiting the E3 ligase TRIM21 to ubiquitinate and degrade PTEN, AP5Z1 hyperactivates the PI3K/Akt/mTOR pathway, making it a promising new biomarker and therapeutic target for liver cancer.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) remains one of the most lethal cancers globally, with incidence rates expected to climb through 2030. Despite advances in multimodal therapy, the prognosis for many patients remains poor due to a lack of early-stage biomarkers and effective therapeutic targets.

The Adaptor Protein (AP) complex family is well-known for its role in protein trafficking and vesicle transport. However, the role of AP5Z1 (a subunit of the more recently discovered AP-5 complex) in cancer has been largely a mystery. This paper investigates whether AP5Z1 "moonlights" as a regulator of oncogenic signaling, specifically looking at how it influences cell proliferation, programmed cell death (apoptosis), and the cellular recycling process known as autophagy.

Methods

The authors employed a comprehensive "bench-to-bedside" approach:

  • Clinical Validation: Analysis of 60 pairs of human HCC tissues and adjacent normal tissues using qRT-PCR, Western Blotting (WB), and Immunohistochemistry (IHC).
  • Bioinformatics: Mining TCGA (The Cancer Genome Atlas) data to correlate AP5Z1 expression with patient survival and tumor stage.
  • Functional Assays: Loss-of-function (knockdown) and gain-of-function (overexpression) experiments in multiple HCC cell lines (SUN-449, LM3, and MHCC-97H).
  • Mechanistic Discovery:
    • Mass Spectrometry (MS) and Co-Immunoprecipitation (Co-IP) to identify proteins that physically interact with AP5Z1.
  • Autophagy Monitoring: Using GFP-mCherry-LC3B dual-fluorescence systems and Transmission Electron Microscopy (TEM) to visualize autophagosomes.
  • Ubiquitination Assays: To prove that AP5Z1 facilitates the chemical tagging (ubiquitination) of PTEN for destruction.
  • In Vivo Models: Subcutaneous xenograft experiments in nude mice to validate findings in a living system.

Datasets

  • TCGA-LIHC: Used for large-scale transcriptomic analysis and survival correlation.
  • Institutional Cohort: 60 clinical HCC samples from the First Affiliated Hospital of Guangxi Medical University.
  • Cell Lines: A panel of HCC lines (MHCC-97H, HUH-7, SUN-182, SUN-449, LM3) and the normal liver cell line MIHA.

Key Insights and Ideas

  • The Recruiter Mechanism: The most significant "aha" moment was discovering that AP5Z1 acts as a molecular matchmaker. It doesn't degrade proteins itself; instead, it recruits the E3 ubiquitin ligase TRIM21 to the tumor suppressor PTEN. This recruitment leads to the rapid degradation of PTEN, effectively "cutting the brakes" on cell growth.
  • Autophagy Suppression: While autophagy can sometimes help cancer cells survive stress, in this context, AP5Z1-mediated suppression of autophagy and apoptosis allows the tumor to proliferate unchecked.
  • Post-Translational Control: Interestingly, AP5Z1 does not change the mRNA levels of PTEN; it only affects the stability of the PTEN protein. This highlights the importance of studying protein-protein interactions rather than just gene expression.

Key Results

  • Clinical Correlation: AP5Z1 is significantly overexpressed in HCC tissues compared to normal liver. High expression levels correlate with larger tumor size, metastasis, advanced TNM stage, and significantly shorter overall survival (OS).
  • Tumor Suppression via Knockdown: Silencing AP5Z1 in aggressive cell lines (SUN-449, LM3) inhibited DNA synthesis, arrested the cell cycle at the G0/G1 phase, and triggered apoptosis.
  • Pathway Activation: Overexpressing AP5Z1 increased the phosphorylation (activation) of PI3K, Akt, and mTOR. This effect could be reversed by the PI3K inhibitor LY294002, confirming the pathway's involvement.
  • In Vivo Efficacy: In mouse models, knocking down AP5Z1 significantly reduced tumor volume and weight. Crucially, knocking down PTEN simultaneously could "rescue" the tumor growth, proving that the AP5Z1-PTEN axis is the primary driver.

Limitations and Future Work

  • Sample Size: While 60 clinical pairs provide a strong signal, the authors acknowledge that larger, multicenter cohorts are needed to validate AP5Z1 as a robust clinical biomarker.
  • Network Complexity: The study focuses heavily on the PTEN/PI3K axis. However, AP5Z1 likely interacts with a broader network of proteins that remain to be mapped.
  • Translational Gap: While the results in mice are promising, developing specific small-molecule inhibitors or gene therapies to target AP5Z1 in humans is a significant future challenge.
  • Biological Context: The study primarily looks at advanced HCC; the role of AP5Z1 in the very early stages of liver cirrhosis or tumorigenesis is still unknown.

Summary updated

Abstract

AP5Z1 influences autophagy and apoptosis in HCC cells by interacting with PTEN to modulate the PI3K/Akt/mTOR pathway. This gene might promote PTEN ubiquitination and degradation by recruiting tripartite motif-containing protein 21 (TRIM21), making it a potential biomarker for diagnosing and predicting the outcome of HCC as well as a target for new treatment strategies.
BibTeX
@article{quan2025ap,
  author = {Zhipeng Quan and Bo Peng and Kai Hu and Lixing Liang and Mingjiang Liu and Lijuan Liao and Shilian Chen and Jing Qin and Songqing He and Zeyuan Li},
  title = {{AP5Z1 affects hepatocellular carcinoma growth and autophagy by regulating PTEN ubiquitination and modulating the PI3K/Akt/mTOR pathway}},
  journal = {Journal of Translational Medicine},
  year = {2025},
  doi = {10.1186/s12967-025-06537-9},
}
Figure